$CCCC 🇺🇸 C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress.. ir.c4therapeutics.com/news-releases/…

$4568.JT & $AZN.SS | $AZN.LN | $AZN 🇯🇵 🇸🇪 🇬🇧 Daiichi Sankyo & AstraZeneca Enhertu showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases astrazeneca.com/media-centre/p… daiichisankyo.com/files/news/pre…

$RO.SW | $ROG.SW | $RHHBY 🇨🇭 Roche FDA Approves Ocrevus Zunovo™ as the First and Only Twice-A-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis gene.com/media/press-re…

$ITOS & $GSK.LN | $GSK 🇧🇪🇬🇧 iTeos & GSK Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in 1L, PD-L1 High Non-Small Cell Lung Cancer Pts investors.iteostherapeutics.com/news-releases/…

$PFE 🇺🇸 Pfizer BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer investors.pfizer.com/Investors/News…

$MRK 🇺🇸 Merck KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma merck.com/news/keytruda-…

$BINV.SS & $TNG.FP 🇸🇪🇫🇷 BioInvent & Transgene Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments storage.mfn.se/534df02b-8751-…

$BCYC 🇺🇸🇬🇧 Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024 investors.bicycletherapeutics.com/news-releases/…

$JNJ 🇺🇸 Johnson & Johnson RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer investor.jnj.com/news/news-deta…

$LLY 🇺🇸 Eli Lilly FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis investor.lilly.com/news-releases/…

$REGN & $SAN.FP | $SNY 🇺🇸🇫🇷 Regeneron & Sanofi Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) investor.regeneron.com/news-releases/…

$NUVL 🇺🇸 Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines investors.nuvalent.com/2024-09-14-Nuv… cc: $PFE .. $RO.SW | $ROG.SW | $RHHBY

$JNJ 🇺🇸 Johnson & Johnson RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer investor.jnj.com/news/news-deta…

$MRK 🇺🇸 Merck KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular.. merck.com/news/keytruda-…

$JNJ 🇺🇸 Johnson & Johnson New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer investor.jnj.com/news/news-deta…